EA202091610A3 - PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOSANIC ACID - Google Patents
PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOSANIC ACIDInfo
- Publication number
- EA202091610A3 EA202091610A3 EA202091610A EA202091610A EA202091610A3 EA 202091610 A3 EA202091610 A3 EA 202091610A3 EA 202091610 A EA202091610 A EA 202091610A EA 202091610 A EA202091610 A EA 202091610A EA 202091610 A3 EA202091610 A3 EA 202091610A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- acid
- phenosanic
- pharmaceutical composition
- hard gelatin
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относится к фармацевтическим композициям фенозановой кислоты и может быть использовано в качестве лекарственного препарата. Технической задачей, решаемой заявленным изобретением, является создание впервые фармацевтической композиции в виде твердой желатиновой капсулы, содержащей фенозановую кислоту. Техническим результатом, достигаемым при реализации заявленного изобретения, является создание впервые фармацевтической композиции в виде твердой желатиновой капсулы, содержащей фенозановую кислоту, и таким образом расширение арсенала противоэпилептических средств, обладающих ноотропным действием. Технический результат достигается за счет того, что фармацевтическая композиция в виде твердой желатиновой капсулы, содержащей фенозановую кислоту и вспомогательные вещества, содержит в мг на одну капсулу: фенозановую кислоту или ее фармацевтически приемлемую соль - 100-200; наполнитель - 10-280; связующее - 2-100; смазывающее - 0,1-5,0; разрыхлитель - 0,5-100.The invention relates to pharmaceutical compositions of phenosanic acid and can be used as a drug. The technical problem solved by the claimed invention is to create for the first time a pharmaceutical composition in the form of a hard gelatin capsule containing phenosanoic acid. The technical result achieved during the implementation of the claimed invention is the creation for the first time of a pharmaceutical composition in the form of a hard gelatin capsule containing phenosanic acid, and thus the expansion of the arsenal of antiepileptic drugs with nootropic action. The technical result is achieved due to the fact that the pharmaceutical composition in the form of a hard gelatin capsule containing phenosanic acid and excipients contains in mg per capsule: phenosanoic acid or its pharmaceutically acceptable salt - 100-200; filler - 10-280; binder - 2-100; lubricating - 0.1-5.0; baking powder - 0.5-100.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019124100A RU2731536C1 (en) | 2019-07-30 | 2019-07-30 | Pharmaceutical compositions containing fenosanic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
EA202091610A2 EA202091610A2 (en) | 2021-02-26 |
EA202091610A3 true EA202091610A3 (en) | 2021-04-30 |
Family
ID=72421712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091610A EA202091610A3 (en) | 2019-07-30 | 2020-07-29 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOSANIC ACID |
Country Status (2)
Country | Link |
---|---|
EA (1) | EA202091610A3 (en) |
RU (1) | RU2731536C1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3928183A1 (en) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | LACTAM-FREE CYCLIC AMINO ACIDS |
ITMI20032399A1 (en) * | 2003-12-09 | 2005-06-10 | Zambon Spa | PHARMACEUTICAL COMPOSITION CONTAINING GABAPENTIN. |
US20110046090A1 (en) * | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
EA017542B1 (en) * | 2011-05-24 | 2013-01-30 | Плива Кроэйша Лтд. | Stable pharmaceutical composition comprising pregabalin, capsule containing the same, method for producing and use thereof |
-
2019
- 2019-07-30 RU RU2019124100A patent/RU2731536C1/en active
-
2020
- 2020-07-29 EA EA202091610A patent/EA202091610A3/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2731536C1 (en) | 2020-09-04 |
EA202091610A2 (en) | 2021-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP17085669A (en) | ORODISPERSABLE DOSING UNIT CONTAINING A STETROL COMPONENT | |
MX2019011491A (en) | Niraparib formulations. | |
EA201992116A1 (en) | PHARMACEUTICAL COMPOSITIONS OF FLOROGLUCINOL AND TRIMETHYLFLOROGLUCINOL | |
EA202090573A1 (en) | COMPOSITIONS OF NIRAPARIBA | |
PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
ZA202103090B (en) | Pharmaceutical formulations of cyclosporine analogs | |
EA202091610A3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOSANIC ACID | |
EA202091611A3 (en) | FILLER-FREE PHARMACEUTICAL COMPOSITION CONTAINING PHENOSANIC ACID | |
EA202091561A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE LENALIDOMIDE SALT | |
EA201592297A1 (en) | AGOMELATIN COMPOSITIONS CONTAINING AGOMELATIN IN THE FORM OF CRYSTALS | |
MX2023001572A (en) | Solid dosage forms of palbociclib. | |
MY191983A (en) | Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same | |
EA201100682A1 (en) | STABLE PHARMACEUTICAL COMPOSITION CONTAINING PREGABALIN, CAPSULE, CONTAINING IT, METHOD OF OBTAINING AND APPLICATION | |
WO2018069805A3 (en) | Method for preparation of liquid oral composition of l-thyroxin | |
RU2017129085A (en) | New N-carbamoylmethyl-4-phenyl-2-pyrrolidone formulation | |
AR016017A1 (en) | PHARMACEUTICAL FORMULATIONS AND PROCESS FOR PREPARATION | |
EA201991381A1 (en) | Composition for the treatment of osteoarthritis | |
UA125700U (en) | ANTIARITHMIC MEANS TO REDUCE MAGNESIUM AND POTASSIUM DEFICIENCY IN THE TABLE | |
MX2021010959A (en) | Improved api stability in softgels. | |
UA123399U (en) | PHARMACEUTICAL COMPOSITION OF CHOLINE ALPHOSCERATE IN MEDICINAL FOR ORAL USE | |
RU2012123302A (en) | A MEDICINE FOR PREVENTING PREDUCTURE AND PROSTATE CANCER, PHARMACEUTICAL COMPOSITION, ACTIVE INGREDIENT OF PHARMACEUTICAL COMPOSITION AND METHOD FOR CHEMOPROPHYLAXIS OF PROSTATE CANCER | |
CO2020002625A2 (en) | Sulfur colloid pharmaceutical compositions and processes thereof | |
WO2022146355A3 (en) | Pharmaceutical capsule compositions of alogliptine | |
NZ710967A (en) | Pharmaceutical compositions containing dexketoprofen and tramadol | |
MX2017014725A (en) | Dropropizine in combination with ambroxol in the dosage form of syrup or tablets. |